- Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium.
Comparison of treatment strategies in de novo pediatric acute lymphoblastic leukemia (ALL) […]
- Placental HTRA1 cleaves alpha-1-antitrypsin to generate a NET-Inhibitory Peptide.
Neutrophil extracellular traps (NETs) are important components of innate immunity. Neonatal neutrophils […]
- Severe thrombocytopenia is sufficient for fetal and neonatal intra-cerebral hemorrhage to occur.
Intra-cerebral hemorrhage (ICH) has a devastating impact on the neonatal population. Whether […]
- SOX11, CD70 and Treg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma.
Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with a heterogeneous […]
- Complement mediates binding and procoagulant effects of ultra-large HIT immune complexes.
Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder mediated by ultra-large immune complexes […]
- Functional characterization of 105 Factor H variants associated with atypical HUS: lessons for variant classification.
Atypical hemolytic uremic syndrome (aHUS) is a life-threatening thrombotic microangiopathy that can […]
- The Protein Landscape of Chronic Lymphocytic Leukemia (CLL).
Many functional consequences of mutations on tumor phenotypes in chronic lymphocytic leukemia […]
- Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study.
Polycythemia vera (PV) is associated with increased risk of thrombosis and hemorrhage. […]
- Immune control of cytomegalovirus reactivation in stem cell transplantation.
The reactivation of viruses from latency after allogeneic stem cell transplantation (SCT) […]
- Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study.
Acute graft-versus-host disease (aGvHD) remains a major threat to successful outcome after […]
- Incidence and Prognosis of Clonal Hematopoiesis in patients with Chronic Idiopathic Neutropenia.
The incidence and prognosis of clonal hematopoiesis in patients with isolated neutropenia […]
- Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy.
Ibrutinib is highly active and produces long-term responses in patients with Waldenström […]
- Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
Effective and tolerable treatments are needed for older patients with classical Hodgkin […]
- Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.
Despite significant progress in the treatment of patients with diffuse large B-cell […]
- Type I interferon is induced by hemolysis and drives antibody-mediated erythrophagocytosis in sickle cell disease.
Patients with sickle cell disease (SCD) suffer from intravascular hemolysis associated vascular […]
- CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma.
Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell related adverse event […]
- Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma.
Enhancers are regulatory regions of DNA, which play a key role in […]
- Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients.
Not available. View the full article @ Haematologica Get PDF with LibKey […]
- Combined effects of plasma von Willebrand factor and platelet measures on the risk of incident venous thromboembolism.
Plasma von Willebrand factor (VWF) and platelet reactivity are both risk factors […]
- Clinical Outcomes After 4.5 Years of Eliglustat Therapy for Gaucher Disease Type 1: Phase 3 ENGAGE Trial Final Results.
Eliglustat, an oral substrate reduction therapy, is approved for eligible adults with […]
- Cohesin mutations in myeloid malignancies.
Cohesin is a multi-subunit protein complex that forms a ring-like structure around […]
- Epigenetic dysregulation in myeloid malignancies.
Epigenetic deregulation is now a well-recognized -though not yet fully understood- mechanism […]
- Gene Expression at a Single Molecule Level: Implications for MDS and AML.
Non-genetic heterogeneity, or gene expression stochasticity, is an important source of variability […]
- Omidubicel Versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized Study.
Omidubicel is an ex vivo expanded hematopoietic progenitor cell, and non-expanded myeloid […]
- RNA modifications in hematopoietic malignancies: A new research frontier.
Both protein-coding and noncoding RNAs can be decorated with a wealth of […]
- Splicing factor mutations in hematologic malignancies.
Mutations in genes encoding RNA splicing factors were discovered nearly ten years […]
- Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: a study of the Chronic Malignancies Working Party of EBMT and the Spanish Myelofibrosis Registry.
Allogeneic hematopoietic cell transplantation (allo-HCT) is increasingly used in older myelofibrosis (MF) […]
- Cardiovascular Phenotypes Predict Clinical Outcomes in Sickle Cell Disease: An echocardiography-based cluster analysis.
This study sought to link cardiac phenotypes in homozygous Sickle Cell Disease […]
- Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the Phase III MabCute study.
Rituximab plus chemotherapy induction followed by rituximab maintenance for up to 2 […]
- Fusion gene detection by RNA sequencing complements diagnostics of acute myeloid leukemia and identifies recurring NRIP1-MIR99AHG rearrangements.
Identification of fusion genes in clinical routine is mostly based on cytogenetics […]
- Fusion genes in acute myeloid leukemia: do acute myeloid leukemia diagnostics need to fuse with RNA-sequencing?
Not available. View the full article @ Haematologica Get PDF with LibKey […]
- RXRA DT448/9PP generates a dominant active variant capable of inducing maturation in acute myeloid leukemia cells.
The retinoid receptors RARA and RXRA contribute to myeloid maturation in both […]
- The GPIbα intracellular tail – role in transducing VWF- and Collagen/GPVI-mediated signaling.
The GPIbT-VWF A1 domain interaction is essential for platelet tethering under high […]
- Too much and not enough: revisiting maintenance rituximab in indolent lymphomas.
Not available. View the full article @ Haematologica Get PDF with LibKey […]
- An exciting RXRA mutant revives interest for retinoids in acute myeloid leukemia.
Not available. View the full article @ Haematologica Get PDF with LibKey […]
- CHIP & HIPs: Clonal Hematopoiesis is Common in Hip Arthroplasty Patients and Associates with Autoimmune Disease.
Clonal hematopoiesis (CH) is an age-related condition predisposing to blood cancer and […]
- Clinical relevance of clonal hematopoiesis in the oldest-old population.
Clonal hematopoiesis of indeterminate potential (CHIP) is associated with increased risk of […]
- PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL.
T-cell acute lymphoblastic leukemia (T-ALL) are aggressive hematological cancers with dismal outcomes, […]
- Tumor suppressor function of Gata2 in Acute Promyelocytic Leukemia.
Most patients with acute promyelocytic leukemia (APL) can be cured with combined […]
- Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia.
The use of high-dose intravenous immune globulin (IVIG) plus anticoagulation is recommended […]
- GPR34 activation potentially bridges lymphoepithelial lesion to genesis of salivary gland MALT lymphoma.
GPR34 translocation and mutation are specifically associated with salivary gland MALT lymphoma […]
- Contact Activation Inhibitor, AB023, in Heparin-Free Hemodialysis: Results of a Randomized Phase 2 Clinical Trial.
End-stage renal disease (ESRD) patients on chronic hemodialysis have repeated blood exposure […]
- CRISPR-targeted MAGT1 insertion restores XMEN patient hematopoietic stem cells and lymphocytes.
‘X-linked MAGT1 deficiency with increased susceptibility to Epstein-Barr virus-infection and N-linked glycosylation […]
- Durable Remissions Following Combined Targeted Therapy in Patients with CLL Harboring TP53 Deletions and/or Mutations.
Fifty-one of 189 evaluable patients from three prospective phase-II trials evaluating a […]
- Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo.
Thalassemia or sickle cell patients with hereditary persistence of fetal hemoglobin (HPFH) […]
- How I Treat: Allogeneic HSCT for adults with Inborn Errors of Immunity.
Inborn Errors of Immunity (IEI) are rare inherited disorders arising from monogenic […]
- Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia.
While genomic alterations drive the pathogenesis of acute myeloid leukemia (AML), traditional […]
- Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease.
Trained immunity (TI) is a pro-inflammatory program induced in monocyte/macrophages upon sensing […]
- Regulation of RNA Polymerase II Activity is Essential for Terminal Erythroid Maturation.
The terminal maturation of human erythroblasts requires significant changes in gene expression […]
- SARS-CoV-2 infection induces the activation of tissue factor-mediated coagulation by activation of acid sphingomyelinase.
SARS-CoV-2 infection is associated with the hypercoagulable state. Tissue factor (TF) is […]
- Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited anti-tumor activity.
The multiple myeloma (MM) mutational landscape has identified alterations in KRAS as […]
- Activated Natural Killer Cells Predict Poor Clinical Prognosis in High-risk B- and T- cell Acute Lymphoblastic Leukemia.
B- and T- cell acute lymphoblastic leukemia (B/T-ALL) may be refractory or […]
- Disruption of a GATA2, TAL1, ERG regulatory circuit promotes erythroid transition in healthy and leukemic stem cells.
Changes in gene regulation and expression govern orderly transitions from hematopoietic stem […]
- Exploring the Pathways to Chronic Lymphocytic Leukemia.
In chronic lymphocytic leukemia (CLL), increasing knowledge of the biology of the […]
- FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice.
Hemophilia A (HA) is a bleeding disorder resulting from deficient Factor VIII […]
- Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
In the phase 3 BOSTON study, patients with multiple myeloma (MM) after […]
- Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
In the phase 3 BOSTON study, patients with multiple myeloma (MM) after […]
- Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): What We Know and Don’t Know.
Development of vaccines to fight COVID19 has been a remarkable medical achievement. […]
- Chimeric Antigen Receptor T-Cells Safety: A pharmacovigilance & meta-analysis study.
Chimeric-Antigen-Receptor T-Cells directed against CD19 (CAR-T) are emerging hematological therapeutics with scarce […]
- Adverse events reported to the U.S. Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel.
The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen […]
